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Background: The Pathway Registry evaluated sphenopa-
latine ganglion (SPG) stimulation for cluster headache
(CH). Previously, in a randomized, double-blind, multi-
center study (Pathway CH-1), 68% of patients experienced
clinically significant improvements. We evaluated long-
term therapeutic effectiveness of SPG stimulation.
Method: Acute pain response following SPG stimulation
and attack frequency reduction were analyzed at 12
months following SPG microstimulator insertion. Acute
effectiveness is relief/freedom from moderate pain, or
freedom from mild pain. Therapeutic responders achieved
acute effectiveness in 50% of attacks by end of stimula-
tion, or 50% attack frequency reduction versus baseline.
Patients were similarly evaluated for 75 and 30% ther-
apeutic response.
Results: Through March 2016, 119 patients were
enrolled. 80 patients (74 chronic CH, 6 episodic CH)
had a microstimulator inserted and progressed through
the 12 month study visit (374 31 days post-insertion,
range 322–475).
In these 80 patients (59 male, 21 female, age 46 12
years), baseline attack frequency was 24.9 20.8 attacks/
week with severely CH impact (HIT-6: 64.0 6.9). 66%
(53/80) were therapeutic responders with a response of
50%. Frequency responders (43/80) reduced attack fre-
quency by 86% (26.5 23.2 to 3.6 6.6 attacks/week,
p< 0.001). Acute responders (25/80) achieved effective
therapy in 87% of attacks (4212/4863) by end of
stimulation.
46% (37/80) of patients experienced a very strong thera-
peutic response of at least 75%; 75% (61/80) experienced
at therapeutic response of at least 30%.
Conclusion: Therapeutic effectiveness of SPG stimulation
in chronic medically refractory cluster patients (Pathway
CH-1 trial) is confirmed in an open label registry of a large
series of cluster patients through 12 months.
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